The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.5, a high estimate of $10.00, ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, ...

As recently as last month, Lexicon Pharmaceuticals Inc. was holding out hope regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Lexicon Pharmaceuticals received a complete response letter from the Food and Drug Administration for its treatment of type 1 diabetes and chronic kidney disease.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 53.33% ...

The FDA rejected sotagliflozin for type 1 diabetes and CKD. Lexicon will focus on LX9211 for diabetic neuropathic pain, with ...

Lexicon Pharmaceuticals received a complete response letter from the Food and Drug Administration for its treatment of type 1 diabetes and chronic kidney disease. The FDA's response, which according ...

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug ...

The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.